JP2017066148A5 - - Google Patents

Download PDF

Info

Publication number
JP2017066148A5
JP2017066148A5 JP2016217326A JP2016217326A JP2017066148A5 JP 2017066148 A5 JP2017066148 A5 JP 2017066148A5 JP 2016217326 A JP2016217326 A JP 2016217326A JP 2016217326 A JP2016217326 A JP 2016217326A JP 2017066148 A5 JP2017066148 A5 JP 2017066148A5
Authority
JP
Japan
Prior art keywords
use according
dextran
dtpa
composition
concentration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016217326A
Other languages
English (en)
Japanese (ja)
Other versions
JP6509796B2 (ja
JP2017066148A (ja
Filing date
Publication date
Priority claimed from US12/362,778 external-priority patent/US20100196272A1/en
Application filed filed Critical
Publication of JP2017066148A publication Critical patent/JP2017066148A/ja
Publication of JP2017066148A5 publication Critical patent/JP2017066148A5/ja
Application granted granted Critical
Publication of JP6509796B2 publication Critical patent/JP6509796B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016217326A 2009-01-30 2016-11-07 ジエチレントリアミン五酢酸(dtpa)−デキストランを放射標識するための組成物 Active JP6509796B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12/362,778 2009-01-30
US12/362,778 US20100196272A1 (en) 2009-01-30 2009-01-30 Compositions for radiolabeling diethylenetriaminepentaacetic acid (dtpa)-dextran

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2015090380A Division JP6040276B2 (ja) 2009-01-30 2015-04-27 ジエチレントリアミン五酢酸(dtpa)−デキストランを放射標識するための組成物

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019071387A Division JP6833892B2 (ja) 2009-01-30 2019-04-03 ジエチレントリアミン五酢酸(dtpa)−デキストランを放射標識するための組成物

Publications (3)

Publication Number Publication Date
JP2017066148A JP2017066148A (ja) 2017-04-06
JP2017066148A5 true JP2017066148A5 (enExample) 2017-06-15
JP6509796B2 JP6509796B2 (ja) 2019-05-08

Family

ID=42395938

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2011547973A Active JP5743905B2 (ja) 2009-01-30 2010-01-28 ジエチレントリアミン五酢酸(dtpa)−デキストランを放射標識するための組成物
JP2015090380A Active JP6040276B2 (ja) 2009-01-30 2015-04-27 ジエチレントリアミン五酢酸(dtpa)−デキストランを放射標識するための組成物
JP2016217326A Active JP6509796B2 (ja) 2009-01-30 2016-11-07 ジエチレントリアミン五酢酸(dtpa)−デキストランを放射標識するための組成物
JP2019071387A Expired - Fee Related JP6833892B2 (ja) 2009-01-30 2019-04-03 ジエチレントリアミン五酢酸(dtpa)−デキストランを放射標識するための組成物
JP2021015866A Withdrawn JP2021088566A (ja) 2009-01-30 2021-02-03 ジエチレントリアミン五酢酸(dtpa)−デキストランを放射標識するための組成物

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2011547973A Active JP5743905B2 (ja) 2009-01-30 2010-01-28 ジエチレントリアミン五酢酸(dtpa)−デキストランを放射標識するための組成物
JP2015090380A Active JP6040276B2 (ja) 2009-01-30 2015-04-27 ジエチレントリアミン五酢酸(dtpa)−デキストランを放射標識するための組成物

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2019071387A Expired - Fee Related JP6833892B2 (ja) 2009-01-30 2019-04-03 ジエチレントリアミン五酢酸(dtpa)−デキストランを放射標識するための組成物
JP2021015866A Withdrawn JP2021088566A (ja) 2009-01-30 2021-02-03 ジエチレントリアミン五酢酸(dtpa)−デキストランを放射標識するための組成物

Country Status (9)

Country Link
US (4) US20100196272A1 (enExample)
EP (2) EP2392012B1 (enExample)
JP (5) JP5743905B2 (enExample)
KR (2) KR101713559B1 (enExample)
CN (1) CN102301429A (enExample)
AU (1) AU2010208624B2 (enExample)
BR (1) BRPI1007487A2 (enExample)
CA (1) CA2750230C (enExample)
WO (1) WO2010087959A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100196272A1 (en) 2009-01-30 2010-08-05 Neoprobe Corporation Compositions for radiolabeling diethylenetriaminepentaacetic acid (dtpa)-dextran
JP6163698B2 (ja) * 2013-03-21 2017-07-19 国立大学法人 千葉大学 マクロファージマンノース受容体を認識する新規多糖金属錯体化合物、及び、その医薬組成物
HK1225623A1 (zh) 2013-07-22 2017-09-15 纳维迪亚生物制药有限公司 用於诊断和治疗与表达cd206的细胞相关的病症的组合物、方法和药盒
US10328149B2 (en) 2014-06-13 2019-06-25 Tenboron Oy Conjugates comprising an anti-EGFR1 antibody
JP6722663B2 (ja) * 2014-07-17 2020-07-15 オハイオ ステート イノベーション ファウンデーション マクロファージおよび他のマンノース結合c型レクチン受容体高発現細胞を標的化するための化合物および組成物、ならびにそれらを使用して治療するおよび診断する方法
US10806803B2 (en) 2014-07-17 2020-10-20 Ohio State Innovation Foundation Compositions for targeting macrophages and other CD206 high expressing cells and methods of treating and diagnosis
EP3744708B1 (en) * 2014-11-13 2023-08-09 Waters Technologies Corporation Calibrant for liquid chromatography calibration of labeled n-glycans
GB201504064D0 (en) 2015-03-10 2015-04-22 Accretion Biotechnology Ltd Method and kits for preparing radionuclide complexes
CN106317237B (zh) * 2015-07-03 2019-07-19 华中科技大学 一种用于spect成像的当归多糖衍生物及其合成方法
CN106188226B (zh) * 2016-07-04 2019-12-24 江苏省原子医学研究所 一种用于淋巴结检查的大分子显像剂及其制备方法
FR3054445B1 (fr) * 2016-07-26 2019-07-05 Laboratoires Cyclopharma Synthese d'une composition d'agent radioactif
US10695450B2 (en) 2016-07-26 2020-06-30 Laboratoires Cyclopharma Synthesis of a radioactive agent composition
US11007272B1 (en) 2016-10-07 2021-05-18 Navidea Biopharmaceuticals, Inc. Compounds and methods for diagnosis and treatment of viral infections
JP6329302B2 (ja) * 2017-05-10 2018-05-23 国立大学法人千葉大学 マクロファージマンノース受容体を認識する新規多糖金属錯体化合物、及び、その医薬組成物
JP7576334B2 (ja) * 2019-03-29 2024-10-31 国立研究開発法人量子科学技術研究開発機構 放射性医薬の製造方法及び放射性医薬
JP2023533405A (ja) 2020-07-08 2023-08-03 ナビディア、バイオファーマスーティカルズ、インコーポレイテッド 均一に定められた分子量のマンノシル化デキストランおよびその誘導体の合成
EP4525882A1 (en) 2022-05-20 2025-03-26 Navidea Biopharmaceuticals, Inc. Cd206 targeted drug delivery vehicles carrying novel bisphosphonate drug payloads via a degradable linker
US12404349B2 (en) 2022-10-03 2025-09-02 Navidea Biopharmaceuticals, Inc. Amide linkages of sugar moieties to amine terminated leashes attached to carbohydrate polymers

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1053508B (it) * 1970-07-06 1981-10-10 Searle & Co Procedimento per prepare composizioni marcate adatte a mettere in evidenza alterazioni della mucosa gastrointestinale prodotto ottenuto e relativo metodo di impiego
US4364920A (en) * 1975-04-30 1982-12-21 Medi-Physics, Inc. Stable diagnostic reagents
US4048296A (en) * 1975-05-27 1977-09-13 Mallinckrodt, Inc. Radiopharmaceutical scanning agents
JPS5569517A (en) * 1978-11-20 1980-05-26 Nippon Mejifuijitsukusu Kk Labelling preparation for labelling of erythrocytes with radio-active technetium
SE465907B (sv) 1984-11-01 1991-11-18 Nyegaard & Co As Diagnosticeringsmedel innehaallande en paramagnetisk metall
US5336762A (en) 1985-11-18 1994-08-09 Access Pharmaceuticals, Inc. Polychelating agents for image and spectral enhancement (and spectral shift)
US4822594A (en) 1987-01-27 1989-04-18 Gibby Wendell A Contrast enhancing agents for magnetic resonance images
CS263561B1 (en) 1987-09-18 1989-04-14 Kery Vladimir Process for preparing water soluble allylderivatives of oligo and polysaccharides
GB8801646D0 (en) * 1988-01-26 1988-02-24 Nycomed As Chemical compounds
US5328679A (en) * 1988-04-01 1994-07-12 Immunomedics, Inc. Methods for technetium/rhenium labeling of proteins
DD286598A5 (de) 1989-06-29 1991-01-31 Adw Der Ddr,Zi F. Mulekularbiologie,De Verfahren zur einfuehrung von primaeren aminogruppen in wasserloesliche polymere
EP0516873A1 (en) * 1991-06-06 1992-12-09 THE STATE of ISRAEL Atomic Energy Commission Soreq Nuclear Research Center A method and kit for protein labelling with 99 mTC
US5789578A (en) 1996-01-11 1998-08-04 Massey University Methods for the preparation of resins with ligands attached thereto through a linking group comprising sulfide, sulfoxide or sulfone functionality
CA2279349C (en) * 1996-02-02 2007-09-25 Rhomed Incorporated Ascorbate-stabilized radiopharmaceutical method and composition
US20010055563A1 (en) * 1999-09-09 2001-12-27 Rhomed Incorporated Post-labeling stabilization of radiolabeled proteins and peptides
US6066309A (en) * 1996-02-02 2000-05-23 Rhomed Incorporated Post-labeling stabilization of radiolabeled proteins and peptides
AU5135698A (en) 1996-11-28 1998-06-22 Nihon Schering K.K. Contrast compound, contrast medium for mri, and method for mri
ATE277642T1 (de) 1999-05-14 2004-10-15 Univ California Makromolekular träger auf basis von dextran fur arzneimittel und diagnosticum abgabe
US6887462B2 (en) * 2001-04-09 2005-05-03 Chiron Corporation HSA-free formulations of interferon-beta
US7666979B2 (en) 2002-03-01 2010-02-23 Bracco International B.V. Methods for preparing multivalent constructs for therapeutic and diagnostic applications and methods of preparing the same
EP2316922B1 (en) * 2002-05-24 2013-05-22 Merck Sharp & Dohme Corp. Neutralizing human anti-IGFR antibody
ES2396368T3 (es) 2003-03-03 2013-02-21 Dyax Corporation Péptidos que se unen específicamente al receptor del HGF (CMET) y usos de los mismos
DK1658848T3 (da) * 2004-10-29 2007-11-26 Pharma Mar Sa Formuleringer omfattende ecteinascidin og et disaccharid
TWI398272B (zh) * 2005-03-08 2013-06-11 Intervet Int Bv 化學定義的安定劑
RU2008117396A (ru) * 2005-10-04 2009-11-10 Альк-Абелло А/С (Dk) Твердая вакцинная композиция
AU2007234612B2 (en) * 2006-12-14 2013-06-27 Johnson & Johnson Regenerative Therapeutics, Llc Protein stabilization formulations
BRPI0808259A2 (pt) * 2007-03-05 2014-07-08 Cadila Healthcare Ltd "formulação, processo de liofilização, formulação liofilizada, e processo para preparar uma formulação liofilizada"
US20100196272A1 (en) 2009-01-30 2010-08-05 Neoprobe Corporation Compositions for radiolabeling diethylenetriaminepentaacetic acid (dtpa)-dextran
HK1225623A1 (zh) 2013-07-22 2017-09-15 纳维迪亚生物制药有限公司 用於诊断和治疗与表达cd206的细胞相关的病症的组合物、方法和药盒
EP3169336A4 (en) 2014-07-17 2018-04-04 Ohio State Innovation Foundation Compositions for targeting macrophages and other cd206 high expressing cells and methods of treating and diagnosis
JP6722663B2 (ja) 2014-07-17 2020-07-15 オハイオ ステート イノベーション ファウンデーション マクロファージおよび他のマンノース結合c型レクチン受容体高発現細胞を標的化するための化合物および組成物、ならびにそれらを使用して治療するおよび診断する方法

Similar Documents

Publication Publication Date Title
JP2017066148A5 (enExample)
JP2015164933A5 (enExample)
JP6833892B2 (ja) ジエチレントリアミン五酢酸(dtpa)−デキストランを放射標識するための組成物
US9211341B2 (en) Method of manufacturing a pharmaceutical composition having chelating type complex micelles
JP2014510728A5 (enExample)
HRP20231504T1 (hr) Polisaharidi kapsule iz bakterije streptococcus pneumoniae i njihovi konjugati
JP2012506448A5 (enExample)
JP2012532185A5 (enExample)
JP2013543505A5 (enExample)
JP2021505661A5 (enExample)
HRP20212027T1 (hr) Formulacije polialkilen oksidne asparaginaze i postupci njihove priprave i uporabe
FI3817751T3 (fi) Vedettömän natriumtiosulfaatin formulaatioita
Gold et al. Combined 90Yttrium‐DOTA‐labeled PAM4 antibody radioimmunotherapy and gemcitabine radiosensitization for the treatment of a human pancreatic cancer xenograft
US10632081B2 (en) Intralymphatic delivery of hyaluronan nanoparticle for cancer metastasis
JP2019512012A5 (enExample)
JP2020520368A5 (enExample)
JP2019521179A5 (enExample)
HRP20201683T1 (hr) Imunogeni pripravak namijenjen upotrebi u terapiji
Kobayashi et al. Pharmacokinetic study of weekly administration dose of paclitaxel in patients with advanced or recurrent gastric cancer in Japan
JP5340964B2 (ja) 腫瘍細胞に対する殺傷効果を備えた修飾されたヒドロキシポリマーコンジュゲート
US20140072604A1 (en) Block Copolymer For Intraperitoneal Administration Containing Anti-Cancer Agent, Micelle Preparation Thereof, And Cancer Therapeutic Agent Comprising The Micelle Preparation As Active Ingredient
HRP20230989T1 (hr) Novi sastavi željeza i metode njihove izrade i upotrebe
JP2014504613A5 (enExample)
HRP20191322T1 (hr) Antitumorska kombinacija koja sadži kabazitaksel i cisplatin
MX2007009312A (es) Preparaciones inyectables de diclofenaco y sus sales farmaceuticamente aceptables.